TerminatedPhase 3

A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2

Stopped: The study was terminated due to administrative reasons

Belgium, France24 participantsStarted 2022-09-02

Plain-language summary

Clinical trial looking at safety and efficacy of suvratoxumab in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients

Age range12 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Colonized with Staphylococcus aureus;
✓. Expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia.

Incidence of nosocomial all-cause pneumonia through 30 days post dose

Timeframe: 30 days

NCT IDNCT05331885

SponsorAridis Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-07-08